Exome Sequencing has become the leading tool for discovery-based research in pre-clinical settings for DNA aberrations.
It is important to understand how various molecular factors affect the underlying variant representation to ensure proper experimental techniques enhance biomarker discovery.
This webinar will focus on oncology or complicated admixed tissues where very low frequency alleles are under investigation, and will cover topics including:
- Effects of sample input (intact DNA, FFPE, ultra-low quantity) and recommendations for input
- Contrasting different target enrichment protocols and describing capture bias
- Determining the appropriate amount of sequencing coverage needed for your genetic problem
- Best practices for determining variants and deriving limit of detection
Vic Weigman, PhD, Associate Director of Translational Genomics, EA
Dr. Weigman has been involved in genomic research for the past 13 years, primarily in data interpretation and algorithm development. Through work at UNC Lineberger Cancer Center under Charles Perou, he worked on developing mechanisms for integrating murine and human drug response data and developed new copy number biomarkers for subtypes of breast cancer. While at EA
Quintiles provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to Pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. EA